Evidence map›Paper›PMID 24636337›Full record

Trial reportLeukemia research2014

Mcl-1 dependence predicts response to vorinostat and gemtuzumab ozogamicin in acute myeloid leukemia.

William E Pierceall, Ryan J Lena, Bruno C Medeiros, Noel Blake, Camille Doykan, Michael Elashoff, Michael H Cardone, Roland B Walter

Abstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Leukemia research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. A Phase I/II Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019
    Trial
  2. Article
  3. Review
  4. Article
  5. CDK9 inhibitors in acute myeloid leukemia.Journal of experimental & clinical cancer research : CR · 2018
    Review
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

William E PierceallEutropics Pharmaceuticals, Inc., Cambridge, MA, United States. Electronic address: wpierceall@eutropics.com.
Ryan J LenaEutropics Pharmaceuticals, Inc., Cambridge, MA, United States.
Bruno C MedeirosStanford University, Stanford, CA, United States.
Noel BlakeEutropics Pharmaceuticals, Inc., Cambridge, MA, United States.
Camille DoykanEutropics Pharmaceuticals, Inc., Cambridge, MA, United States.
Michael ElashoffEutropics Pharmaceuticals, Inc., Cambridge, MA, United States.
Michael H CardoneEutropics Pharmaceuticals, Inc., Cambridge, MA, United States.
Roland B WalterClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States; Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, United States; Department of Epidemiology, University of Washington, Seattle, WA, United States. Electronic address: rwalter@fhcrc.org.

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4M
Impact of genetic variation on response to GO therapy in COG-AML clinical trialsR21CA155524 · NCI · UNIVERSITY OF MINNESOTA · PI LAMBA, JATINDER K., WALTER, ROLAND BRUNO · 2012 to 2013
$439k
NCI NIH HHS HHSN261201200039CNCI NIH HHS HHSN261201200039INCI NIH HHS HHSN261201200085CNCI NIH HHS P30 CA015704NCI NIH HHS P30-CA015704-35S6NCI NIH HHS R21 CA155524PHS HHS HHSN261201299985C
6 · The paper itself

Abstract

Older adults with acute myeloid leukemia (AML) are commonly considered for investigational therapies, which often only benefit subsets of patients. In this study, we assessed whether BH3 profiling of apoptotic functionality could predict outcomes following treatment with vorinostat (histone deacetylase inhibitor) and gemtuzumab ozogamicin (GO; CD33-targeted immunoconjugate). Flow cytometry of BH3 peptide priming with Noxa (anti-apoptotic protein Mcl-1 modulator) correlated with remission induction (p=.026; AUC=0.83 [CI: 0.65-1.00; p=.00042]: AUC=0.88 [CI:0.75-1.00] with age adjustment) and overall survival (p=.027 logistic regression; AUC=0.87 [0.64-1.00; p=.0017]). This Mcl-1-dependence suggests a pivotal role of Bcl-2 family protein-mediated apoptosis to vorinostat/GO in AML patients.

Indexed as

AgedAged, 80 and overAminoglycosidesAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsFemaleGemtuzumabHumansHydroxamic AcidsLeukemia, Myeloid, AcuteLogistic ModelsMaleMiddle AgedMyeloid Cell Leukemia Sequence 1 ProteinPeptide FragmentsProto-Oncogene ProteinsAminoglycosidesAntibodies, Monoclonal, HumanizedBax protein (53-86)GemtuzumabHydroxamic AcidsMCL1 protein, humanMyeloid Cell Leukemia Sequence 1 ProteinPeptide FragmentsPMAIP1 protein, humanProto-Oncogene ProteinsProto-Oncogene Proteins c-bcl-2VorinostatAMLBiomarkerGemtuzumab ozogamicinHDAC inhibitorsPersonalized medicine

Identifiers

PMID24636337
PMCPMC4104771

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.